Our understanding of familial predisposition to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia [CLL]) outside of rare hereditary syndromes has progressed rapidly during the last decade. First-degree relatives of NHL, HL and CLL patients have an approximately 1.7-fold, 3.1-fold, and 8.5-fold elevated risk of developing NHL, HL and CLL, respectively. These familial risks are elevated for multiple lymphoma subtypes and do not appear to be confounded by non-genetic risk factors, suggesting at least some shared genetic etiology across the lymphoma subtypes. However, a family history of a specific subtype is most strongly associated with risk for that subtype, supporting subtype-specific genetic factors. While candidate gene studies have had limited success in identifying susceptibility loci, genome-wide association studies (GWAS) have successfully identified 67 single nucleotide polymorphisms from 41 loci, predominately associated with specific subtypes. In general, these GWAS-discovered loci are common (minor allele frequency >5%), have small effect sizes (odds ratios of 0.60-2.0), and are of largely unknown function. The relatively low incidence of lymphoma, modest familial risk, and the lack of a screening test and associated intervention all argue against active clinical surveillance for lymphoma in affected families at this time.
Introduction
Lymphomas, defined as non-Hodgkin (NHL), Hodgkin (HL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (herein CLL), are the most common hematologic malignancies in western countries, and combined there are an estimated 95,520 newly diagnosed cases each year in the United States. 1 While there has been a long history of case reports of familial clustering of lymphomas and leukemias, it has only been relatively recently that these malignancies were considered to have an important inherited genetic component outside of very rare hereditary cancer syndromes. 2 In 2001, the World Health Organization (WHO) introduced an updated classification system for lymphomas based on the REAL classification, 3 which became the international gold-standard. 4 This classification provided the first biologically based, integrated framework for consistently defining lymphoma subtypes, thereby greatly facilitating research on this heterogeneous group of diseases.
Building from prior reviews, [5] [6] [7] [8] [9] [10] [11] we focus on the strongest data addressing familial predisposition (including twin, case-control and registry-based studies) and germline susceptibility loci (including linkage and genetic association studies) for lymphoma, and put these findings into clinical context. One emerging theme on the etiology of lymphoma is that there is both commonality and heterogeneity for risk factors by subtype, 12 and thus we consider this issue as well in the context of familial predisposition and genetic risk factors.
Evidence for Familial Predisposition

Twin Studies
If the concordance rate of a phenotype in monozygotic twins (who share all genes) is higher than the concordance rate for dizygotic twins (who share on average half of their genes), then there is evidence for a genetic component. In a study of 44,788 pairs of twins from Scandinavia, 13 there was an excess of concordant monozygotic twins compared to dizygotic twins for leukemia, and the heritability was estimated to be 21% (95%CI 0-0.54); these results
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14 There were insufficient cases to estimate heritability for NHL or HL. In a twin study of lymphomas, 15 there was a 100-fold higher risk of HL in monozygotic twins of patients with HL compared background rates (SIR=99; 95%CI 48-182), while there was no excess risk in dizygotic twins; in contrast, there was a 23-fold higher risk of NHL in monozygotic twins of patients with NHL and a 14-fold higher risk in dizygotic twins, suggesting a stronger role for shared environment for NHL.
Familial aggregation (Table 1)
We summarize the strongest results across different study designs that evaluate the extent that family history of lymphoma is associated with risk of developing lymphoma, including casecontrol, cohort and registry-based studies. We note that none of these study designs can definitively establish an inherited genetic contribution to risk of lymphoma as these approaches are unable to distinguish the role of shared genetics from shared environment. Family size itself may also be associated with lymphoma risk, which can introduce bias in estimating the association of familial aggregation with lymphoma risk.
Case-Control Studies. In case-control studies, the prevalence of a family history is compared in case patients to that of controls using an odds ratio (OR) to quantify the magnitude of risk. The largest study to date is a pooled analysis of 17,471 NHL cases and 23,096 controls from 20
case-control studies in the International Lymphoma Epidemiology Consortium (InterLymph), 12 which found an 1. These data provide strong evidence for familial predisposition to lymphoma. However, the case-control study design is susceptible to several types of bias, particularly selection and reporting bias. The former bias can occur when there are systematic differences in how cases and controls are enrolled, most commonly due to exclusion of more aggressive cases (who die
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 6 before they can be enrolled into a study) and how controls are selected (i.e., controls who are not representative of the underlying population that generated the cases due to selection factors or participation rates). The main concern with reporting bias is that cases and controls can differentially report a family history. In a study from Scandinavia that compared self-report to cancer registry data, 25 specificity of reporting a hematologic malignancy was very high for both cases (98%) and controls (99%), while sensitivity was much lower at 60% for cases and only 38% for controls. This led to inflated odds ratios (up to 30%) based on self-reported family history data. 35 It is notable that most of the risk estimates from the populationbased registry studies in Table 1 were very similar or only modestly weaker than the estimates from the pooled case-control studies, again suggesting that there was only modest bias in estimates from case-control studies. The most prominent exception is for a family history of CLL, which showed a much stronger association in the registry studies compared to that of case-control studies. This may be in part due to the confusion of patients reporting a CLL as a leukemia or lymphoma.
The registry studies have also been able to evaluate risk for more detailed lymphoma subtypes. One striking finding is the clustering of risk by NHL subtype. For example, firstdegree relatives of DLBCL cases had a 9.8-fold increased risk of DLBCL, 36 first-degree relatives of FL had a 4-fold increased risk of FL, 36 and first-degree relatives of LPL/WM had a 20-fold increased risk of LPL/WM. 37 In contrast, risk of a different subtype was much weaker, and notably relatives of DLBCL patients were not at increased risk of FL and relatives of FL patients
were not at increased risk of DLBCL. 36 There are very limited data on PTCL, and registry data suggests no increased risk among first-degree relatives with HL, CLL, DLBCL, or FL.
36
Summary. Multiple lines of data suggest that a family history of lymphoma is associated with an increased risk of lymphoma, familial risk is elevated for multiple lymphoma subtypes, and familial risk does not seem to be confounded by non-genetic risk factors, although there are likely unidentified risk factors and clustering of known (and unknown) risk factors within families is difficult to exclude. This suggests at least some shared genetic etiology across the lymphoma subtypes. However, because a family history of a specific lymphoma subtype is also most strongly associated with risk for that specific lymphoma, genetic factors are also likely to be unique to a subtype.
Genetic Risk Factors
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We now review studies that show not only clear evidence of a genetic contribution to lymphoma risk, but also provide chromosomal locations that are associated with risk.
Linkage Studies
Linkage studies use multi-case families or sib pairs to screen the genome in an unbiased manner to identify chromosomal regions that show excessive sharing of inherited alleles among affected individuals. These regions can then be interrogated for causal variants using a variety of approaches, most commonly fine-mapping using dense genotyping or sequencing. The expectation is to identify highly penetrant variants of modest to large effect size, although these variants are generally rare or very rare in the general population. Linkage studies in HL have identified both HLA class I (for EBV+) and class II (for EBV-) risk and protective alleles and haplotypes. 10, 11 Beyond HLA, linkage studies in CLL, 38 HL, 39 and WM 40 have not definitively identified genes with large effects, and there are no published studies in FL, DLBCL or other NHL subtypes. For CLL, significant linkage was identified at 2q21.2, which contains the chemokine receptor (CXCR4) gene and for which rare coding mutations have been identified. 41 The lack of strong findings for these linkage studies may be due to small sample sizes, but also raises the hypothesis that multiple, low to moderate risk variants that are common in the population, defined as minor allele frequency (MAF) >5%, may be more relevant in lymphoma etiology than single, highly penetrant variants that are very rare, which is referred to as the common-disease, common-variant hypothesis. 42 
Genetic Association Studies
With the advent of high-throughput and relatively inexpensive genotyping technologies, casecontrol studies (also commonly called association studies in the genetics literature) of sequence variation in germline DNA have become a predominant study design in genetic epidemiology.
This design is a very efficient strategy to identify low penetrance alleles relative to linkage studies, which are underpowered for this task. 44 The most common type of genetic variation in the human genome is the single nucleotide polymorphism (SNP), which is a single base pair change in the DNA sequence. In this setting, SNP allele or genotype frequencies in cases (patients) are compared to that in unrelated controls (who do not have the phenotype of interest) using an OR. When the genetic model (e.g., dominant vs. recessive) is not known a priori, the OR is typically modeled as "per risk allele" (i.e., ordinal test of 0, 1 or 2 risk alleles). While other genetic variation is of interest, including rare variants (<5% frequency), insertion/deletions, block substitutions, inversions, translocations and copy number alterations, these have not been studied as extensively. 45 Two major types of association studies are candidate gene and genome-wide association studies (GWAS).
Candidate Gene Studies
The choice of a candidate gene has been mainly driven by a priori biologic knowledge of lymphoma and diseases associated with lymphoma (e.g., infectious or autoimmune), or results identified in other cancers. Candidate gene studies have included pathways related to immune function, cell cycle/proliferation, apoptosis, DNA repair, and carcinogen metabolism. Early studies tended to evaluate a small number of genes (i.e., <5) and were generally restricted to 1 or 2 SNPs within a gene. These SNPs often had some evidence for their functionality based on laboratory data or anticipated changes in protein coding or gene activity (e.g., changes in promotor function). As genotyping technologies increased in throughput and decreased in cost, more SNPs within genes and more genes (often grouped into pathways) were assessed. Also, the International Haplotype Map ("HapMap") 46 and later the 1000 Genomes 47 projects, which catalogue human genetic variation, became available as a reference and allowed "tagging" of genes and gene regions to take advantage of linkage disequilibrium (LD) to efficiently cover all of the common genetic variation for more comprehensive genotyping studies. 
GWAS (Table 2)
In contrast to candidate gene/pathway studies, GWA studies use dense microarrays with a large number of SNPs (commonly 250,000 to 750,00 or more) spread across all chromosomes to identify genetic markers associated with case-control status. 54 While SNPs on these platforms have generally focused on common variants (MAF≥5%), more recent arrays are enriching for rarer variants (MAF<5%). GWAS is considered agnostic ("hypothesis-free") as all loci are considered equally. Given the large number of statistical tests involved, a stringent level of evidence (currently P<5 x 10 -8 ) and replication across multiple independent studies are required to declare an association as "genome-wide significant." An advantage of having a large number of typed SNPs is that any underlying difference in population structure between cases and controls can be identified and controlled to ensure that confounding by race/ethnicity does not bias the results.
CLL. The estimated contribution of all common variation to the heritability of CLL is 46-59%.
55,56
The first GWAS in a lymphoid malignancy was conducted for CLL 57 In an East Asian population, GWAS-discovered SNPs for CLL near IRF4 (rs872071), SP140
(rs13397985), and ACOXL (rs17483466) were associated with CLL risk (nominal P<0.05), with a suggestive association with GRAMD1B (rs735665). 63 The minor allele frequencies of these SNPs were much lower than in populations of European descent, supporting the hypothesis that the lower prevalence of CLL genetic risk factors might explain part of the lower incidence of CLL in East Asian populations.
FL. Three early GWA studies based on small discovery sets (<400 cases) identified loci at 6p21.33 64 and 6p21.32 65, 66 in the major histocompatibility complex (MHC) associated with FL.
In a meta-analysis of those studies plus a new GWAS of over 2100 cases, the HLA region showed overwhelming association with FL, with 8,104 SNPs achieving genome-wide significance. A top SNP from this region, rs12195582, reached P=5.35x10 -100 after additional validation. 67 HLA alleles and amino acids (AA) were imputed and the top signal mapped to four linked DRβ1 multiallelic AA at positions at 11, 13, 28 and 30, suggesting an important role for DRβ1 peptide presentation in FL. 67 Additional independent signals were also identified in HLA class II (rs17203612) and class I (rs3130437, near HLA-C); after accounting for all of these [77] [78] [79] and support a role for class I but not class II genes in EBV+ HL. Using SNPs to impute classic HLA alleles, two independent signals in the HLA class II region (rs6903608 and rs2281389)
were linked to early onset HL, but no specific classical HLA alleles from this region were significant after conditioning on these two SNPs. 76 The class II SNP rs6903608 was estimated to account for ~6% of the familial risk in HL. 76 Outside of the MHC region, GWAS-discovered loci for HL include 2p16. SNPs, which was much rarer.
MZL. The only GWAS of this subtype 83 identified two distinct loci at 6p21.32 (intragenic to BTNL2, in HLA class II) and 6p21.33 (HLA-B, in HLA class I); these two loci were in low LD and were statistically independent of each other. There was no strong heterogeneity in these results when stratified on mucosa associated lymphoid tissue (MALT) versus non-MALT (splenic MZL and nodal MZL) subtypes, although this was based on a modest sample size. These loci are also associated with autoimmune diseases and immune response, suggesting shared biologic underpinnings with MZL.
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Summary
To date, GWAS have successfully identified 67 SNPs from 41 genetic loci, mainly associated with specific subtypes (Figure 1) , with only two regions-the HLA region and 8q24-associated with multiple lymphoma subtypes; few candidate gene loci have been replicated by GWAS. As shown in Figure 2 , the established loci are common (minor allele frequency >5%) and have small effect sizes, supporting a polygenic model for susceptibility. In contrast to GWAS, candidate gene studies in lymphoma have had only minimal success, similar to other cancers. 85 Linkage studies have also not been successful in identifying rare alleles causing Mendelian disease, and the evaluation of low-frequency variants with intermediate effects is still in early research phases for lymphoma, but will be challenged by sample size issues. 86 The GWASidentified SNPs that have been identified are largely of unknown function. However, a leading hypothesis related for the mechanistic role of these common SNPs is their effect on gene expression (e.g., through effects on promotors or enhancers), but this effect is difficult to identify given an expected modest impact of these SNPs on gene expression and the fact that this impact could occur at any time before diagnosis.
61
Practice Implications
Given the estimated lifetime risk of NHL is 1 in 48 (2.1%) in the United States 1 and an RR of 1.7
for the risk of NHL in a first-degree relative, then the absolute lifetime risk of NHL is 3.6% in firstdegree relatives of an NHL patient. The absolute risk is even lower for specific lymphoma
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From subtypes, which are less common. While the absolute lifetime risk of NHL is not trivial, the relatively low incidence of lymphoma, the modest familial risk, and the lack of a screening test and associated intervention all argue against active clinical surveillance of family members of lymphoma patients at this time. One hope is that genetic risk scores, alone or in combination with other risk factors, might improve prediction ability. 87 While there are currently no validated risk scores for lymphoma, this advance is anticipated as more loci are characterized.
Future Directions
Characterization of genetic susceptibility in lymphoma is rapidly evolving. It is expected that additional common variants will be discovered for the different lymphoma subtypes, 88 and perhaps pan-lymphoma loci will also be identified. As new lymphoma entities and precursor lesions are defined, evaluation of heritability and genetic susceptibility should be addressed.
Additional work needs to occur in other racial and ethnic groups, particularly with contrasting lymphoma incidence rates. It is not yet clear if rare and low-frequency variants will play a major role in lymphoma susceptibility. This will be challenging to address due to phenotype heterogeneity and the need for large sample sizes for these relatively rare entities, and both family and association study designs along with bioinformatics and laboratory-based studies will all need to be integrated to achieve progress. 86 Other genetic mechanisms (e.g., copy number variation), epigenetics and gene-environment interactions are additional frontiers. 85 Finally, integrating somatic and germline genomics should provide additional insights into lymphoma etiology and pathogenesis, 89 and hopefully provide novel insights into how to prevent and treat this malignancy.
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